Suggested remit: To appraise the clinical and cost effectiveness of dacomitinib within its marketing authorisation for treating epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer that has not previously been treated.
 
Status In progress
Process STA pre-2018
ID number 1346

Provisional Schedule

Expected publication 28 August 2019

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Warwick Evidence

Consultees

Companies sponsors Pfizer (dacomitinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  Cancer Research UK
  National Lung Cancer Forum for Nurses
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies AstraZeneca (gefitinib)
  Boehringer Ingelheim (afatinib) (Confidentiality agreement not signed, not participating)
  Roche (erlotinib) (Confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Cancer Research Institute

Timeline

Key events during the development of the guidance:

Date Update
23 May 2019 Committee meeting: 2
10 April 2019 - 09 May 2019 Appraisal consultation
20 March 2019 Committee meeting: 1
10 October 2018 Invitation to participate
04 June 2018 - 02 July 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
05 December 2017 In progress, DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance